Our Company Who we are Board of directors Team Stakeholders Our programs Pipeline Stage of Development Clinical Studies Media Contact
Clinical Studies Media Contact

Press & Media

OneChain Immunotherapeutics Presents Promising New Data on OC-1d at ISCT 2025 [Pdf]
7 May 2025
OneChain Immunotherapeutics S.L and NanoCell Therapeutics Inc. Announce Collaboration on In Vivo CAR-T Therapy for B-cell Lymphoma [Pdf]
16 May 2024
[Press Release] - First patient treated in OneChain Immunotherapeutics' CAR T trial [Pdf]
07 May 2024
[Press release] OneChain Immunotherapeutics participates in a consortium receiving a €3.8 million grant for the design of in vivo targeted viral particles for in vivo CAR-T using AI [Pdf]
04 March 2024
[Press release] Rare Disease Day - New promising therapy for a rare leukemia [Pdf]
29 Feb 2024
[Press Release] OneChain Immunotherapeutics appoints new CEO [Pdf]
2 Feb 2024
[Press Release] OneChain Immunotherapeutics achieves FDA Orphan Drug designation for OC-1
3 Oct 2023
NdP OneChain Immunotherapeutics secures €6.7M in pre-series A funding round
22 Jun 2023
Promising therapy to treat an aggressive type of leukemia receives 2.5 million euros from the EU to reach patients
23 Feb 2023
Autorizado un ensayo clínico único en el mundo con tecnología CAR-T para pacientes con un subtipo de Leucemia de células T
21 Dec 2022
(Spanish) Fundación Carreras crea 'spin-off' para desarrollar terapia inmunooncológica
20 Jul 2020
(Spanish) Invivo Ventures, CDTI-Innvierte y la Fundación Josep Carreras cierran una ronda de financiación de 3.050.000€ en OneChain Immunotherapeutics
20 Jul 2020